Psoriasis Drug Market
Psoriasis Drug Market Study by Interleukin Inhibitors, Corticosteroids, Anti-inflammatory, and Tumor Necrosis Factor Inhibitors from 2024 to 2034
Analysis of Psoriasis Drug Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Psoriasis Drug Market Outlook (2024 to 2034)
Worldwide sales of psoriasis drugs are expected to reach US$ 14.08 billion in 2024 and further increase at a CAGR of 6.9% to climb to US$ 27.57 billion by 2034-end.
The requirement for psoriasis drugs is increasing as the disease becomes more and more prevalent among people. Psoriasis is a chronic and long-lasting disease that attacks the immune system and makes it overactive, causing the skin cells to multiply too quickly.
Discomfort and pain experienced by those afflicted with this illness escalate, resulting in a growing need for medications to speed up their healing process. The cause of psoriasis is not understood fully yet quite a few drugs are available in the market that offer relief to people.
Key Market Growth Drivers
- According to the American Academy of Dermatology, around 2% of people living in the United States suffer from psoriasis.
- Suppliers in the market are recognizing this trend and actively establishing their presence in regions with high demand for such drugs.
- Psoriasis is among the diseases where a significant number of individuals inherit genes associated with its development. Given its genetic nature, suppliers can make accurate estimates of their future customer base, thereby increasing the profitability of psoriasis drug suppliers.
- Psoriasis is notably triggered by factors such as smoking, heavy alcohol consumption, and cold weather. Manufacturers are heavily investing to capitalize on this opportunity to enhance their profit margins.
- Typically, it takes one year or longer to achieve remission, but major players in the market are investing heavily in research and development to speed up and simplify treatment, potentially opening new avenues for suppliers and boosting psoriasis drug market growth.
- Consumers generally prefer purchasing drugs from retail pharmacies and hospitals, prompting drug suppliers to closely align with such healthcare facilities to enhance their sales. All of these factors thus contribute to market expansion.
| Report Attributes | Details |
|---|---|
| Psoriasis Drug Market Size (2024E) | US$ 14.08 Billion |
| Forecasted Market Value (2034F) | US$ 27.57 Billion |
| Global Market Growth Rate (2024 to 2034) | 6.9% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 8.2% CAGR |
| Brazil Market Value (2034F) | US$ 1.01 Billion |
| North America Market Share (2024E) | 29.9% |
| Latin America Market Share (2034F) | 10.4% |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Psoriasis Drug Market Trends Beneficial to Manufacturers?
“Focus on Use of Biologics for Effective Disease Management to Minimize Side Effects”
Recent links between psoriasis and arthritis, as well as mental health issues, have emerged as opportunistic platforms for manufacturers seeking to create innovative biologics with long-term effectiveness.
Treatment with new biologics, such as tumor necrosis factor and interleukin, is proposed to successfully control plaque psoriasis with few to no side effects and long-term benefits. Thus, research into the production of innovative biologics or biological pharmaceuticals has provided a resourceful approach to psoriasis management, and this feature is projected to aid the expansion of the psoriasis drug market as an alternative to traditional treatment approaches.
Increasing number of psoriasis patients worldwide has prompted manufacturing businesses to launch research and development initiatives to provide innovative psoriasis treatments. A strong product pipeline and rising regulatory approvals for drugs such as Stelara (Janssen Pharmaceuticals) and Cimzia (UCB S.A.) are helping boost the adoption of psoriasis treatment in many regions.
“Increasing Regulatory Approvals for New Treatment Options”
Biologics, also known as biological therapy, are among the most popular choices for treating psoriasis. Several multinational corporations have recognized the launch of new products as a prime opportunity for market expansion. Furthermore, industry participants are focusing on strategic alliances and mergers, leading to the development of various breakthrough products.
- For instance, in December 2021, Amgen Inc. received the United States FDA clearance for Otezla to treat mild to moderate plaque psoriasis in adults. These initiatives have enabled the company to expand its product portfolio for oral delivery.
What is Affecting the Profitability of Psoriasis Drug Suppliers?
“High Medical Expenses Associated with Psoriasis Treatment”
One of the key reasons limiting demand for psoriasis medications is the high medical expenses involved in treating psoriasis. A cohort study released in 2017 found that more than 8 million people in the United States had psoriasis. Comorbidities were associated with increased healthcare resource use and expenditures among psoriasis patients.
As manufacturers strive to produce innovative biological treatments, significant spending on drug development for regulatory approvals and the complex patent filing procedure are also impeding psoriasis drug market growth.
- According to the National Psoriasis Foundation, psoriasis-related costs in the United States might reach US$ 135 billion each year. Additionally, a lack of understanding regarding psoriasis and its accompanying comorbidities is a significant barrier to market expansion, resulting in underdiagnosis and inadequate treatment.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Evaluation
Psoriasis has been prominently affecting people living in regions with cold weather including countries like the United States and Canada. The market in Canada is projected to expand at a CAGR of 8.2% from 2024 to 2034. Latin America accounts for a significant psoriasis drug market share, with the Chile market projected to expand at a CAGR of 5.8% from 2024 to 2034.
Why is the United States a Lucrative Market for Psoriasis Drug Manufacturers?
“Advanced Medical Infrastructure and Favorable Reimbursement Policies for Psoriasis Treatment”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 3.52 Billion |
| Growth Rate (2024 to 2034) | 7.7% CAGR |
| Projected Value (2034F) | US$ 7.41 Billion |
High incidence of psoriasis and the increasing use of prescription dermatological treatments for psoriasis care are driving market growth. Moreover, the country's substantial market share may be attributed to its well-developed healthcare infrastructure, the presence of major psoriasis drug producers, and favorable government reimbursement regulations for psoriasis treatments.
What are the Opportunities for Psoriasis Drug Manufacturers in Brazil?
“Market Benefitting from Improved Access to Healthcare”
| Attribute | Brazil |
|---|---|
| Market Value (2024E) | US$ 596 Million |
| Growth Rate (2024 to 2034) | 5.4% CAGR |
| Projected Value (2034F) | US$ 1.01 Billion |
Experts believe that psoriasis is caused by a combination of hereditary and environmental factors. People's lifestyles in industrialized and developing nations, including Brazil, have changed as their discretionary incomes have increased. Some causes of psoriasis include an unhealthy lifestyle, poor eating habits, and alcohol consumption. Smoking and a sedentary lifestyle are two factors that increase the risk of developing such diseases. Brazilians now have better access to healthcare, making them aware of both the treatment for the ailment and its causes.
Category-wise Insights
A variety of drug types are available in the market for psoriasis, including topical, oral, and injectable. Demand for oral psoriasis drugs is forecast to rise at a CAGR of 7.1% from 2024 to 2034. The hospital segment is projected to expand at a CAGR of 7.4% through 2034.
Which Drug Class Do Healthcare Providers Recommend for Psoriasis Treatment?
“Preference for Corticosteroids Due to Their Proven Effectiveness”
| Attribute | Corticosteroids |
|---|---|
| Segment Value (2024E) | US$ 4.91 Billion |
| Growth Rate (2024 to 2034) | 7.2% CAGR |
| Projected Value (2034F) | US$ 9.88 Billion |
Corticosteroids, commonly referred to as steroids, are a type of anti-inflammatory drug typically used to treat rheumatological diseases such as psoriasis. These steroids have been proven to be highly effective and efficient, winning the hearts of consumers. Healthcare providers largely prefer this type of drug over others. Manufacturers in the psoriasis drug market have responded to this trend by increasing the production of corticosteroids, enhancing their dominance in the market.
Which Indication Accounts for a Significant Share of the Market?
“Focus of Healthcare Providers on Efficient Management of Guttate Psoriasis”
| Attribute | Guttate Psoriasis |
|---|---|
| Segment Value (2024E) | US$ 400 Million |
| Growth Rate (2024 to 2034) | 11.1% CAGR |
| Projected Value (2034F) | US$ 1.14 Billion |
Psoriasis patients commonly experience various manifestations of the disease, including guttate psoriasis, inverse psoriasis, pustular psoriasis, and plaque psoriasis. Among these, guttate psoriasis holds particular significance, prompting drug suppliers to prioritize its treatment. Guttate psoriasis is characterized by as small, red, and scaly spots on the arms and legs, with its name derived from the Latin term "gutta," meaning drop. Suppliers are actively focusing on addressing this condition and researching methods to mitigate its effects.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the psoriasis drug industry are working on developing new treatments and promoting existing brands to increase market share. To increase product penetration, psoriasis medicine makers are focusing on new marketing methods.
Companies continue to see clearance and product launches as essential components of their growth strategies. They are also focusing on constructing a value chain for a key regional market, as well as creating new psoriasis medications and long-term solutions, contributing to the evolving psoriasis drug market trends such as immune checkpoint inhibitors and injectable drug delivery.
- Amgen stated in February 2021 that it had submitted a supplementary New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Otezla® (apremilast) to treat people with mild-to-moderate plaque psoriasis.
Key Segments of Psoriasis Drug Market Research
-
By Product Type :
- Topical Psoriasis Drugs
- Oral Psoriasis Drugs
- Injectable Psoriasis Drugs
-
By Drug Class :
- Interleukin Inhibitors
- Corticosteroids
- Anti-inflammatory
- Tumor Necrosis Factor Inhibitors
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
-
By Indication :
- Guttate Psoriasis
- Inverse Psoriasis
- Pustular Psoriasis
- Erythrodermic Psoriasis
- Plaque Psoriasis
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Key Findings 1.1.1. Overall Market 1.1.2. Segment Overview 1.1.3. Regional Overview 1.1.4. Competitor’s Focus 1.1.5. Consumer’s Perception 1.2. Summary of Statistics 1.3. Market Characteristics and Attributes 2. Market Overview 2.1. Introduction and Definition 2.2. Research Scope 3. Market Background 3.1. Country-wise Market Attractiveness Index 3.2. Market Scenario-based Forecast 3.3. Value Chain Analysis 3.3.1. List of Manufacturers 3.3.2. List of Online Retailers 3.3.3. List of Distribution Channels 3.4. Investment Feasibility Assessment 3.4.1. Investment Feasibility for Market 3.5. Porter’s Five Forces Analysis 3.5.1. Bargaining Power of Buyers 3.5.2. Bargaining Power of Suppliers 3.5.3. Threat of Substitute Drug Classs 3.5.4. Threat of New Entrants 3.5.5. Intensity of Rivalry 3.5.6. 5 Forces Acting Upon Market 3.6. PESTEL Analysis 3.7. Forecast Factors 3.7.1. Increasing Government Regulations 3.7.2. Expansion of Industry 3.7.3. Compliance to Insurance Regulations 3.7.4. Advancements in Market 3.7.5. Increasing Global Temperature 3.7.6. Technological Advancements 3.8. Market Dynamics 3.8.1. Market Drivers 3.8.2. Market Restraints 3.8.3. Opportunity Windows 3.8.4. Key Trends 4. Global Market Pricing Analysis 4.1. Price Point Assessment 4.1.1. Weighted Average Pricing (2023), by Region 4.1.2. Key Factors Influencing Pricing 4.1.3. Price Benchmark by Region 4.1.4. Price Benchmark by Product Type 5. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034) 5.1. Market Overview 5.2. Introduction to Market Statistics 5.2.1. Global Market Value (US$ Mn) 5.2.2. Global Cumulative Historical Market and Absolute $ Opportunity 5.3. Y-o-Y Growth and Incremental Opportunity 5.4. Absolute Dollar Historical Market and Absolute Dollar Opportunity 6. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Product Type 6.1. Introduction 6.1.1. Product Type Definition 6.1.1.1. Topical Psoriasis Drugs 6.1.1.2. Oral Psoriasis Drugs 6.1.1.3. Injectable Psoriasis Drugs 6.1.2. Market Key Findings, by Product Type 6.1.2.1. Absolute $ Opportunity (2024 to 2034) 6.1.2.2. Market Share and BPS Analysis 6.1.2.3. Y-o-Y Growth Projections 6.1.2.4. Market Attractiveness Analysis 6.2. Global Market Regional Market Share Comparison, by Product Type 7. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Drug Class 7.1. Introduction 7.1.1. Drug Class Definition 7.1.1.1. Interleukin Inhibitors 7.1.1.2. Corticosteroids 7.1.1.3. Anti-inflammatory 7.1.1.4. Tumor Necrosis Factor Inhibitors 7.1.2. Market Key Findings, by Drug Class 7.1.2.1. Absolute $ Opportunity (2024 to 2034) 7.1.2.2. Market Share and BPS Analysis 7.1.2.3. Y-o-Y Growth Projections 7.1.2.4. Market Attractiveness Analysis 7.2. Global Market Regional Market Share Comparison, by Drug Class 8. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Indication 8.1. Introduction 8.1.1. Indication Definition 8.1.1.1. Guttate Psoriasis 8.1.1.2. Inverse Psoriasis 8.1.1.3. Pustular Psoriasis 8.1.1.4. Erythrodermic Psoriasis 8.1.1.5. Plaque Psoriasis 8.1.2. Market Key Findings, by Indication 8.1.2.1. Absolute $ Opportunity (2024 to 2034) 8.1.2.2. Market Share and BPS Analysis 8.1.2.3. Y-o-Y Growth Projections 8.1.2.4. Market Attractiveness Analysis 8.2. Global Market Regional Market Share Comparison, by Indication 9. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Distribution Channel 9.1. Introduction 9.1.1. Distribution Channel Definition 9.1.1.1. Hospital Pharmacies 9.1.1.2. Retail Pharmacies 9.1.1.3. e-Commerce 9.1.2. Market Key Findings, by Distribution Channel 9.1.2.1. Absolute $ Opportunity (2024 to 2034) 9.1.2.2. Market Share and BPS Analysis 9.1.2.3. Y-o-Y Growth Projections 9.1.2.4. Market Attractiveness Analysis 9.2. Global Market Regional Market Share Comparison, by Distribution Channel 10. Global Market Analysis (2018 to 2023) and Forecast (2024 to 2034), by Region 10.1. Introduction 10.1.1. Regional Coverage 10.1.1.1. North America 10.1.1.2. Europe 10.1.1.3. East Asia 10.1.1.4. South Asia 10.1.1.5. Latin America 10.1.1.6. Middle East & Africa (MEA) 10.1.1.7. Oceania 10.1.2. Market Key Findings, by Region 10.1.2.1. Absolute $ Opportunity (2024 to 2034) 10.1.2.2. Market Share and BPS Analysis 10.1.2.3. Y-o-Y Growth Projections 10.1.2.4. Market Attractiveness Analysis 10.2. Global Market Regional Market Share Comparison, by Region 11. North America Market Analysis and Forecast 11.1. Overview 11.1.1. North America Share in Global Market 11.2. Market Value & Volume Forecast and Analysis 11.2.1. By Country 11.2.1.1. United States 11.2.1.2. Canada 11.2.2. By Product Type 11.2.3. By Drug Class 11.2.4. By Indication 11.2.5. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.1.1. United States 11.3.1.2. Canada 11.3.2. By Product Type 11.3.3. By Drug Class 11.3.4. By Indication 11.3.5. By Distribution Channel 11.4. Y-o-Y Growth Comparison 12. Europe Market Analysis and Forecast 12.1. Overview 12.1.1. Europe Share in Global Market 12.2. Market Value & Volume Forecast and Analysis 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Russia 12.2.1.5. Spain 12.2.1.6. Italy 12.2.1.7. Rest of Europe 12.2.2. By Product Type 12.2.3. By Drug Class 12.2.4. By Indication 12.2.5. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.1.1. Germany 12.3.1.2. United Kingdom 12.3.1.3. France 12.3.1.4. Russia 12.3.1.5. Spain 12.3.1.6. Italy 12.3.1.7. Rest of Europe 12.3.2. By Product Type 12.3.3. By Drug Class 12.3.4. By Indication 12.3.5. By Distribution Channel 12.4. Y-o-Y Growth Comparison 13. East Asia Market Analysis and Forecast 13.1. Overview 13.1.1. East Asia Share in Global Market 13.2. Market Value & Volume Forecast and Analysis 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Product Type 13.2.3. By Drug Class 13.2.4. By Indication 13.2.5. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.1.1. China 13.3.1.2. Japan 13.3.1.3. South Korea 13.3.2. By Product Type 13.3.3. By Drug Class 13.3.4. By Indication 13.3.5. By Distribution Channel 13.4. Y-o-Y Growth Comparison 14. South Asia Market Analysis and Forecast 14.1. Overview 14.1.1. South Asia Share in Global Market 14.2. Market Value & Volume Forecast and Analysis 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Singapore 14.2.1.3. Indonesia 14.2.1.4. Thailand 14.2.1.5. Rest of South Asia 14.2.2. By Product Type 14.2.3. By Drug Class 14.2.4. By Indication 14.2.5. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.1.1. India 14.3.1.2. Singapore 14.3.1.3. Indonesia 14.3.1.4. Thailand 14.3.1.5. Rest of South Asia 14.3.2. By Product Type 14.3.3. By Drug Class 14.3.4. By Indication 14.3.5. By Distribution Channel 14.4. Y-o-Y Growth Comparison 15. Latin America Market Analysis and Forecast 15.1. Overview 15.1.1. Latin America Share in Global Market 15.2. Market Value & Volume Forecast and Analysis 15.2.1. By Country 15.2.1.1. Brazil 15.2.1.2. Mexico 15.2.1.3. Rest of LATAM 15.2.2. By Product Type 15.2.3. By Drug Class 15.2.4. By Indication 15.2.5. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.1.1. Brazil 15.3.1.2. Mexico 15.3.1.3. Rest of LATAM 15.3.2. By Product Type 15.3.3. By Drug Class 15.3.4. By Indication 15.3.5. By Distribution Channel 15.4. Y-o-Y Growth Comparison 16. Middle East & Africa Market Analysis and Forecast 16.1. Overview 16.1.1. Middle East & Africa Share in Global Market 16.2. Market Value & Volume Forecast and Analysis 16.2.1. By Country 16.2.1.1. Turkey 16.2.1.2. GCC Countries 16.2.1.3. Rest of MEA 16.2.2. By Product Type 16.2.3. By Drug Class 16.2.4. By Indication 16.2.5. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.1.1. Turkey 16.3.1.2. GCC Countries 16.3.1.3. Rest of MEA 16.3.2. By Product Type 16.3.3. By Drug Class 16.3.4. By Indication 16.3.5. By Distribution Channel 16.4. Y-o-Y Growth Comparison 17. Oceania Market Analysis and Forecast 17.1. Overview 17.1.1. Oceania Share in Global Market 17.2. Market Value & Volume Forecast and Analysis 17.2.1. By Country 17.2.1.1. Australia 17.2.1.2. New Zealand 17.2.2. By Product Type 17.2.3. By Drug Class 17.2.4. By Indication 17.2.5. By Distribution Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Product Type 17.3.3. By Drug Class 17.3.4. By Indication 17.3.5. By Distribution Channel 17.4. Y-o-Y Growth Comparison 18. Global Market Analysis Key Countries 18.1. United States 18.1.1. Share of North American Market 18.1.2. Market Share, by Product Type, 2023 18.1.3. Market Share, by Drug Class, 2023 18.1.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.1.5. Market Share, by Distribution Channel, 2023 18.2. Canada 18.2.1. Share of North American Market 18.2.2. Market Share, by Product Type, 2023 18.2.3. Market Share, by Drug Class, 2023 18.2.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.2.5. Market Share, by Distribution Channel, 2023 18.3. Germany 18.3.1. Share of European Market 18.3.2. Market Share, by Product Type, 2023 18.3.3. Market Share, by Drug Class, 2023 18.3.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.3.5. Market Share, by Distribution Channel, 2023 18.4. United Kingdom 18.4.1. Share of European Market 18.4.2. Market Share, by Product Type, 2023 18.4.3. Market Share, by Drug Class, 2023 18.4.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.4.5. Market Share, by Distribution Channel, 2023 18.5. France 18.5.1. Share of European Market 18.5.2. Market Share, by Product Type, 2023 18.5.3. Market Share, by Drug Class, 2023 18.5.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.5.5. Market Share, by Distribution Channel, 2023 18.6. Russia 18.6.1. Share of European Market 18.6.2. Market Share, by Product Type, 2023 18.6.3. Market Share, by Drug Class, 2023 18.6.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.6.5. Market Share, by Distribution Channel, 2023 18.7. Spain 18.7.1. Share of European Market 18.7.2. Market Share, by Product Type, 2023 18.7.3. Market Share, by Drug Class, 2023 18.7.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.7.5. Market Share, by Distribution Channel, 2023 18.8. Italy 18.8.1. Share of European Market 18.8.2. Market Share, by Product Type, 2023 18.8.3. Market Share, by Drug Class, 2023 18.8.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.8.5. Market Share, by Distribution Channel, 2023 18.9. China 18.9.1. Share of East Asian Market 18.9.2. Market Share, by Product Type, 2023 18.9.3. Market Share, by Drug Class, 2023 18.9.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.9.5. Market Share, by Distribution Channel, 2023 18.10. Japan 18.10.1. Share of East Asian Market 18.10.2. Market Share, by Product Type, 2023 18.10.3. Market Share, by Drug Class, 2023 18.10.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.10.5. Market Share, by Distribution Channel, 2023 18.11. South Korea 18.11.1. Share of East Asian Market 18.11.2. Market Share, by Product Type, 2023 18.11.3. Market Share, by Drug Class, 2023 18.11.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.11.5. Market Share, by Distribution Channel, 2023 18.12. India 18.12.1. Share of South Asian Market 18.12.2. Market Share, by Product Type, 2023 18.12.3. Market Share, by Drug Class, 2023 18.12.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.12.5. Market Share, by Distribution Channel, 2023 18.13. Singapore 18.13.1. Share of South Asian Market 18.13.2. Market Share, by Product Type, 2023 18.13.3. Market Share, by Drug Class, 2023 18.13.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.13.5. Market Share, by Distribution Channel, 2023 18.14. Indonesia 18.14.1. Share of South Asian Market 18.14.2. Market Share, by Product Type, 2023 18.14.3. Market Share, by Drug Class, 2023 18.14.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.14.5. Market Share, by Distribution Channel, 2023 18.15. Thailand 18.15.1. Share of South Asian Market 18.15.2. Market Share, by Product Type, 2023 18.15.3. Market Share, by Drug Class, 2023 18.15.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.15.5. Market Share, by Distribution Channel, 2023 18.16. Brazil 18.16.1. Share of Latin American Market 18.16.2. Market Share, by Product Type, 2023 18.16.3. Market Share, by Drug Class, 2023 18.16.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.16.5. Market Share, by Distribution Channel, 2023 18.17. Mexico 18.17.1. Share of Latin American Market 18.17.2. Market Share, by Product Type, 2023 18.17.3. Market Share, by Drug Class, 2023 18.17.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.17.5. Market Share, by Distribution Channel, 2023 18.18. Turkey 18.18.1. Share of MEA Market 18.18.2. Market Share, by Product Type, 2023 18.18.3. Market Share, by Drug Class, 2023 18.18.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.18.5. Market Share, by Distribution Channel, 2023 18.19. GCC Countries 18.19.1. Share of MEA Market 18.19.2. Market Share, by Product Type, 2023 18.19.3. Market Share, by Drug Class, 2023 18.19.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.19.5. Market Share, by Distribution Channel, 2023 18.20. South Africa 18.20.1. Share of MEA Market 18.20.2. Market Share, by Product Type, 2023 18.20.3. Market Share, by Drug Class, 2023 18.20.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.20.5. Market Share, by Distribution Channel, 2023 18.21. Australia 18.21.1. Share of Oceania Market 18.21.2. Market Share, by Product Type, 2023 18.21.3. Market Share, by Drug Class, 2023 18.21.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.21.5. Market Share, by Distribution Channel, 2023 18.22. New Zealand 18.22.1. Share of Oceania Market 18.22.2. Market Share, by Product Type, 2023 18.22.3. Market Share, by Drug Class, 2023 18.22.4. Market Value (US$ Mn) and Forecast 2024 to 2034 18.22.5. Market Share, by Distribution Channel, 2023 19. Competition Landscape 19.1. Global Market Competition Dashboard 19.2. Global Market Tier Structure 19.2.1. Market Structure in 2023 19.2.2. Anticipated Market Structure in 2034 19.3. Global Market Share Analysis 20. Competition Analysis 20.1. Amgen Inc. 20.1.1. Company Overview 20.1.2. Drug Class Portfolio 20.1.3. Key Strategies 20.1.4. Regional Presence 20.1.5. Key Developments 20.1.6. SWOT Analysis 20.2. Eli Lilly and Company 20.2.1. Company Overview 20.2.2. Drug Class Portfolio 20.2.3. Key Strategies 20.2.4. Regional Presence 20.2.5. Key Developments 20.2.6. SWOT Analysis 20.3. Novartis 20.3.1. Company Overview 20.3.2. Drug Class Portfolio 20.3.3. Key Strategies 20.3.4. Regional Presence 20.3.5. Key Developments 20.3.6. SWOT Analysis 20.4. Johnson & Johnson 20.4.1. Company Overview 20.4.2. Drug Class Portfolio 20.4.3. Key Strategies 20.4.4. Regional Presence 20.4.5. Key Developments 20.4.6. SWOT Analysis 20.5. AstraZeneca Plc 20.5.1. Company Overview 20.5.2. Drug Class Portfolio 20.5.3. Key Strategies 20.5.4. Regional Presence 20.5.5. Key Developments 20.5.6. SWOT Analysis 20.6. LEO Pharma A/S 20.6.1. Company Overview 20.6.2. Drug Class Portfolio 20.6.3. Key Strategies 20.6.4. Regional Presence 20.6.5. Key Developments 20.6.6. SWOT Analysis 20.7. Biogen Inc. 20.7.1. Company Overview 20.7.2. Drug Class Portfolio 20.7.3. Key Strategies 20.7.4. Regional Presence 20.7.5. Key Developments 20.7.6. SWOT Analysis 20.8. Sun Pharmaceutical Industries 20.8.1. Company Overview 20.8.2. Drug Class Portfolio 20.8.3. Key Strategies 20.8.4. Regional Presence 20.8.5. Key Developments 20.8.6. SWOT Analysis 20.9. Pfizer Inc. 20.9.1. Company Overview 20.9.2. Drug Class Portfolio 20.9.3. Key Strategies 20.9.4. Regional Presence 20.9.5. Key Developments 20.9.6. SWOT Analysis 20.10. Celgene Corporation 20.10.1. Company Overview 20.10.2. Drug Class Portfolio 20.10.3. Key Strategies 20.10.4. Regional Presence 20.10.5. Key Developments 20.10.6. SWOT Analysis 20.11. Boehringer Ingelheim 20.11.1. Company Overview 20.11.2. Drug Class Portfolio 20.11.3. Key Strategies 20.11.4. Regional Presence 20.11.5. Key Developments 20.11.6. SWOT Analysis 20.12. Merck 20.12.1. Company Overview 20.12.2. Drug Class Portfolio 20.12.3. Key Strategies 20.12.4. Regional Presence 20.12.5. Key Developments 20.12.6. SWOT Analysis 21. Appendix 22. Definitions of Analytical Frameworks 23. Sources and References
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market by Product Type, 2018 to 2034
Table 02: Global Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 03: Global Market by Drug Class, 2018 to 2034
Table 04: Global Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 05: Global Market by Indication, 2018 to 2034
Table 06: Global Market Value (US$ Mn), by Indication, 2018 to 2034
Table 07: Global Market by Distribution Channel, 2018 to 2034
Table 08: Global Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 09: Global Market by Region, 2018 to 2034
Table 10: Global Market Value (US$ Mn), by Region, 2018 to 2034
Table 11: North America Market by Product Type, 2018 to 2034
Table 12: North America Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 13: North America Market by Drug Class, 2018 to 2034
Table 14: North America Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 15: North America Market by Indication, 2018 to 2034
Table 16: North America Market Value (US$ Mn), by Indication, 2018 to 2034
Table 17: North America Market by Distribution Channel, 2018 to 2034
Table 18: North America Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 19: North America Market by Country, 2018 to 2034
Table 20: North America Market Value (US$ Mn), by Country, 2018 to 2034
Table 21: Europe Market by Product Type, 2018 to 2034
Table 22: Europe Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 23: Europe Market by Drug Class, 2018 to 2034
Table 24: Europe Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 25: Europe Market by Indication, 2018 to 2034
Table 26: Europe Market Value (US$ Mn), by Indication, 2018 to 2034
Table 27: Europe Market by Distribution Channel, 2018 to 2034
Table 28: Europe Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 29: Europe Market by Country, 2018 to 2034
Table 30: Europe Market Value (US$ Mn), by Country, 2018 to 2034
Table 31: East Asia Market by Product Type, 2018 to 2034
Table 32: East Asia Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 33: East Asia Market by Drug Class, 2018 to 2034
Table 34: East Asia Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 35: East Asia Market by Indication, 2018 to 2034
Table 36: East Asia Market Value (US$ Mn), by Indication, 2018 to 2034
Table 37: East Asia Market by Distribution Channel, 2018 to 2034
Table 38: East Asia Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 39: East Asia Market by Country, 2018 to 2034
Table 40: East Asia Market Value (US$ Mn), by Country, 2018 to 2034
Table 41: South Asia Market by Product Type, 2018 to 2034
Table 42: South Asia Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 43: South Asia Market by Drug Class, 2018 to 2034
Table 44: South Asia Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 45: South Asia Market by Indication, 2018 to 2034
Table 46: South Asia Market Value (US$ Mn), by Indication, 2018 to 2034
Table 47: South Asia Market by Distribution Channel, 2018 to 2034
Table 48: South Asia Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 49: South Asia Market by Country, 2018 to 2034
Table 50: South Asia Market Value (US$ Mn), by Country, 2018 to 2034
Table 51: Latin America Market by Product Type, 2018 to 2034
Table 52: Latin America Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 53: Latin America Market by Drug Class, 2018 to 2034
Table 54: Latin America Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 55: Latin America Market by Indication, 2018 to 2034
Table 56: Latin America Market Value (US$ Mn), by Indication, 2018 to 2034
Table 57: Latin America Market by Distribution Channel, 2018 to 2034
Table 58: Latin America Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 59: Latin America Market by Country, 2018 to 2034
Table 60: Latin America Market Value (US$ Mn), by Country, 2018 to 2034
Table 61: Middle East and Africa Market by Product Type, 2018 to 2034
Table 62: Middle East and Africa Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 63: Middle East and Africa Market by Drug Class, 2018 to 2034
Table 64: Middle East and Africa Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 65: Middle East and Africa Market by Indication, 2018 to 2034
Table 66: Middle East and Africa Market Value (US$ Mn), by Indication, 2018 to 2034
Table 67: Middle East and Africa Market by Distribution Channel, 2018 to 2034
Table 68: Middle East and Africa Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 69: Middle East and Africa Market by Country, 2018 to 2034
Table 70: Middle East and Africa Market Value (US$ Mn), by Country, 2018 to 2034
Table 71: Oceania Market by Product Type, 2018 to 2034
Table 72: Oceania Market Value (US$ Mn), by Product Type, 2018 to 2034
Table 73: Oceania Market by Drug Class, 2018 to 2034
Table 74: Oceania Market Value (US$ Mn), by Drug Class, 2018 to 2034
Table 75: Oceania Market by Indication, 2018 to 2034
Table 76: Oceania Market Value (US$ Mn), by Indication, 2018 to 2034
Table 77: Oceania Market by Distribution Channel, 2018 to 2034
Table 78: Oceania Market Value (US$ Mn), by Distribution Channel, 2018 to 2034
Table 79: Oceania Market by Country, 2018 to 2034
Table 80: Oceania Market Value (US$ Mn), by Country, 2018 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Fig 01: Global Market Value (US$) and Y-o-Y Growth, 2018 to 2034
Fig 02: Global Absolute $ Historical Market (2018 to 2023) and Absolute $ Opportunity (2024 to 2034), US$ Mn
Fig 03: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2034
Fig 04: Global Market Incremental $ Opportunity (US$ Thousand), 2024 to 2034
Fig 05: Global Market Share, By Product Type – 2024 to 2034
Fig 06: Global Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 07: Global Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 08: Global Market Share, By Drug Class – 2024 to 2034
Fig 09: Global Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 10: Global Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 11: Global Market Share, By Indication – 2024 to 2034
Fig 12: Global Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 13: Global Market Attractiveness Index, By Indication – 2024 to 2034
Fig 14: Global Market Share, By Distribution Channel – 2024 to 2034
Fig 15: Global Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 16: Global Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 17: Global Market Share, by Region – 2024 to 2034
Fig 18: Global Market Y-o-Y Growth Projections, by Region – 2024 to 2034
Fig 19: Global Market Attractiveness Index, by Region – 2024 to 2034
Fig 20: Y-o-Y Growth Comparison of Market: North America Vs North America Countries Vs North America Average
Fig 21: North America Market Share, By Product Type – 2024 to 2034
Fig 22: North America Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 23: North America Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 24: North America Market Share, By Drug Class – 2024 to 2034
Fig 25: North America Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 26: North America Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 27: North America Market Share, By Indication – 2024 to 2034
Fig 28: North America Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 29: North America Market Attractiveness Index, By Indication – 2024 to 2034
Fig 30: North America Market Share, By Distribution Channel – 2024 to 2034
Fig 31: North America Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 32: North America Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 33: North America Market Share, By Country – 2024 to 2034
Fig 34: North America Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 35: North America Market Attractiveness Index, By Country – 2024 to 2034
Fig 36: Y-o-Y Growth Comparison of Market: Europe Vs Europe Countries Vs Europe Average
Fig 37: Europe Market Share, By Product Type – 2024 to 2034
Fig 38: Europe Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 39: Europe Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 40: Europe Market Share, By Drug Class – 2024 to 2034
Fig 41: Europe Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 42: Europe Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 43: Europe Market Share, By Indication – 2024 to 2034
Fig 44: Europe Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 45: Europe Market Attractiveness Index, By Indication – 2024 to 2034
Fig 46: Europe Market Share, By Distribution Channel – 2024 to 2034
Fig 47: Europe Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 48: Europe Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 49: Europe Market Share, By Country – 2024 to 2034
Fig 50: Europe Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 51: Europe Market Attractiveness Index, By Country – 2024 to 2034
Fig 52: Y-o-Y Growth Comparison of Market: East Asia Vs East Asia Countries Vs East Asia Average
Fig 53: East Asia Market Share, By Product Type – 2024 to 2034
Fig 54: East Asia Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 55: East Asia Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 56: East Asia Market Share, By Drug Class – 2024 to 2034
Fig 57: East Asia Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 58: East Asia Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 59: East Asia Market Share, By Indication – 2024 to 2034
Fig 60: East Asia Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 61: East Asia Market Attractiveness Index, By Indication – 2024 to 2034
Fig 62: East Asia Market Share, By Distribution Channel – 2024 to 2034
Fig 63: East Asia Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 64: East Asia Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 65: East Asia Market Share, By Country – 2024 to 2034
Fig 66: East Asia Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 67: East Asia Market Attractiveness Index, By Country – 2024 to 2034
Fig 68: Y-o-Y Growth Comparison of Market: South Asia Vs South Asia Countries Vs South Asia Average
Fig 69: South Asia Market Share, By Product Type – 2024 to 2034
Fig 70: South Asia Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 71: South Asia Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 72: South Asia Market Share, By Drug Class – 2024 to 2034
Fig 73: South Asia Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 74: South Asia Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 75: South Asia Market Share, By Indication – 2024 to 2034
Fig 76: South Asia Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 77: South Asia Market Attractiveness Index, By Indication – 2024 to 2034
Fig 78: South Asia Market Share, By Distribution Channel – 2024 to 2034
Fig 78: South Asia Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 80: South Asia Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 81: South Asia Market Share, By Country – 2024 to 2034
Fig 82: South Asia Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 83: South Asia Market Attractiveness Index, By Country – 2024 to 2034
Fig 84: Y-o-Y Growth Comparison of Market: Latin America Vs Latin America Countries Vs Latin America Average
Fig 85: Latin America Market Share, By Product Type – 2024 to 2034
Fig 86: Latin America Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 87: Latin America Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 88: Latin America Market Share, By Drug Class – 2024 to 2034
Fig 89: Latin America Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 90: Latin America Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 91: Latin America Market Share, By Indication – 2024 to 2034
Fig 92: Latin America Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 93: Latin America Market Attractiveness Index, By Indication – 2024 to 2034
Fig 94: Latin America Market Share, By Distribution Channel – 2024 to 2034
Fig 95: Latin America Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 96: Latin America Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 97: Latin America Market Share, By Country – 2024 to 2034
Fig 98: Latin America Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 99: Latin America Market Attractiveness Index, By Country – 2024 to 2034
Fig 100: Y-o-Y Growth Comparison of Market: MEA Vs MEA Countries Vs MEA Average
Fig 101: MEA Market Share, By Product Type – 2024 to 2034
Fig 102: MEA Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 103: MEA Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 104: MEA Market Share, By Drug Class – 2024 to 2034
Fig 105: MEA Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 106: MEA Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 107: MEA Market Share, By Indication – 2024 to 2034
Fig 108: MEA Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 109: MEA Market Attractiveness Index, By Indication – 2024 to 2034
Fig 110: MEA Market Share, By Distribution Channel – 2024 to 2034
Fig 111: MEA Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 112: MEA Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 113: MEA Market Share, By Country – 2024 to 2034
Fig 114: MEA Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 115: MEA Market Attractiveness Index, By Country – 2024 to 2034
Fig 116: Y-o-Y Growth Comparison of Market: Oceania Vs Oceania Countries Vs Oceania Average
Fig 117: Oceania Market Share, By Product Type – 2024 to 2034
Fig 118: Oceania Market Y-o-Y Growth Projections, By Product Type – 2024 to 2034
Fig 119: Oceania Market Attractiveness Index, By Product Type – 2024 to 2034
Fig 120: Oceania Market Share, By Drug Class – 2024 to 2034
Fig 121: Oceania Market Y-o-Y Growth Projections, By Drug Class – 2024 to 2034
Fig 122: Oceania Market Attractiveness Index, By Drug Class – 2024 to 2034
Fig 123: Oceania Market Share, By Indication – 2024 to 2034
Fig 124: Oceania Market Y-o-Y Growth Projections, By Indication – 2024 to 2034
Fig 125: Oceania Market Attractiveness Index, By Indication – 2024 to 2034
Fig 126: Oceania Market Share, By Distribution Channel – 2024 to 2034
Fig 127: Oceania Market Y-o-Y Growth Projections, By Distribution Channel – 2024 to 2034
Fig 128: Oceania Market Attractiveness Index, By Distribution Channel – 2024 to 2034
Fig 129: Oceania Market Share, By Country – 2024 to 2034
Fig 130: Oceania Market Y-o-Y Growth Projections, By Country – 2024 to 2034
Fig 131: Oceania Market Attractiveness Index, By Country – 2024 to 2034
Fig 132: United States Market share by Product Type, 2023
Fig 133: United States Market share by Drug Class, 2023
Fig 134: United States Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 135: United States Market Share by Distribution Channel, 2023
Fig 136: Canada Market share by Product Type, 2023
Fig 137: Canada Market share by Drug Class, 2023
Fig 138: Canada Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 139: Canada Market Share by Distribution Channel, 2023
Fig 140: Germany Market share by Product Type, 2023
Fig 141: Germany Market share by Drug Class, 2023
Fig 142: Germany Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 143: Germany Market Share by Distribution Channel, 2023
Fig 144: United Kingdom Market share by Product Type, 2023
Fig 145: United Kingdom Market share by Drug Class, 2023
Fig 146: United Kingdom Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 147: United Kingdom Market Share by Distribution Channel, 2023
Fig 148: France Market share by Product Type, 2023
Fig 149: France Market share by Drug Class, 2023
Fig 150: France Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 151: France Market Share by Distribution Channel, 2023
Fig 152: Russia Market share by Product Type, 2023
Fig 153: Russia Market share by Drug Class, 2023
Fig 154: Russia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 155: Russia Market Share by Distribution Channel, 2023
Fig 156: Spain Market share by Product Type, 2023
Fig 157: Spain Market share by Drug Class, 2023
Fig 158: Spain Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 159: Spain Market Share by Distribution Channel, 2023
Fig 160: Italy Market share by Product Type, 2023
Fig 161: Italy Market share by Drug Class, 2023
Fig 162: Italy Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 163: Italy Market Share by Distribution Channel, 2023
Fig 164: China Market share by Product Type, 2023
Fig 165: China Market share by Drug Class, 2023
Fig 166: China Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 167: China Market Share by Distribution Channel, 2023
Fig 168: Japan Market share by Product Type, 2023
Fig 169: Japan Market share by Drug Class, 2023
Fig 170: Japan Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 171: Japan Market Share by Distribution Channel, 2023
Fig 172: South Korea Market share by Product Type, 2023
Fig 173: South Korea Market share by Drug Class, 2023
Fig 174: South Korea Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 175: South Korea Market Share by Distribution Channel, 2023
Fig 176: India Market share by Product Type, 2023
Fig 177: India Market share by Drug Class, 2023
Fig 178: India Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 179: India Market Share by Distribution Channel, 2023
Fig 180: Singapore Market share by Product Type, 2023
Fig 181: Singapore Market share by Drug Class, 2023
Fig 182: Singapore Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 183: Singapore Market Share by Distribution Channel, 2023
Fig 184: Indonesia Market share by Product Type, 2023
Fig 185: Indonesia Market share by Drug Class, 2023
Fig 186: Indonesia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 187: Indonesia Market Share by Distribution Channel, 2023
Fig 188: Thailand Market share by Product Type, 2023
Fig 189: Thailand Market share by Drug Class, 2023
Fig 190: Thailand Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 191: Thailand Market Share by Distribution Channel, 2023
Fig 192: Brazil Market share by Product Type, 2023
Fig 193: Brazil Market share by Drug Class, 2023
Fig 194: Brazil Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 195: Brazil Market Share by Distribution Channel, 2023
Fig 196: Mexico Market share by Product Type, 2023
Fig 197: Mexico Market share by Drug Class, 2023
Fig 198: Mexico Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 199: Mexico Market Share by Distribution Channel, 2023
Fig 200: Turkey Market share by Product Type, 2023
Fig 201: Turkey Market share by Drug Class, 2023
Fig 202: Turkey Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 203: Turkey Market Share by Distribution Channel, 2023
Fig 204: GCC Countries Market share by Product Type, 2023
Fig 205: GCC Countries Market share by Drug Class, 2023
Fig 206: GCC Countries Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 207: GCC Countries Market Share by Distribution Channel, 2023
Fig 208: South Africa Market share by Product Type, 2023
Fig 209: South Africa Market share by Drug Class, 2023
Fig 210: South Africa Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 211: South Africa Market Share by Distribution Channel, 2023
Fig 212: Australia Market share by Product Type, 2023
Fig 213: Australia Market share by Drug Class, 2023
Fig 214: Australia Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 215: Australia Market Share by Distribution Channel, 2023
Fig 216: New Zealand Market share by Product Type, 2023
Fig 217: New Zealand Market share by Drug Class, 2023
Fig 218: New Zealand Market Value (US$ Mn) and Forecast 2024 to 2034
Fig 219: New Zealand Market Share by Distribution Channel, 2023
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the psoriasis drug market size in 2024?
The global market for psoriasis drugs stands at US$ 14.08 billion in 2024.
What is the projected revenue from psoriasis drug sales for 2034?
By 2034, worldwide revenue from psoriasis drug sales is projected to reach US$ 27.57 billion.
How fast are psoriasis medicine sales projected to increase?
Psoriasis medicine sales are forecasted to increase at 6.9% CAGR through 2034.
What is the sales forecast for psoriasis drugs in North America?
The market in North America is forecasted to increase at 7.8% CAGR from 2024 to 2034.
At what rate is the market projected to expand in Latin America?
The market in Latin America is projected to expand at a CAGR of 5.5% from 2024 to 2034.
What are the projections for the market in the Rest of LATAM?
Sales in the Rest of LATAM are forecasted to rise at a CAGR of 5.3% from 2024 to 2034.
Psoriasis Drug Market